Last 46 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Semler Scientific, Inc.'s quarterly P/E stands at 7.0x, down 14.3% year-over-year — suggesting improving earnings relative to price.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 3.96 | 7.01 | 1.92 | — | 3.96 | 8.18 | 6142.86 | 9.36 | 20.13 | 8.93 | 8.75 | 10.63 | 20.12 |
| — | -14.3% | -100.0% | — | -80.3% | -8.5% | +70130.8% | -12.0% | +0.0% | -56.2% | -36.7% | -64.8% | -84.2% | |
| P/S Ratio | 5.52 | 16.57 | 15.89 | 9.83 | 9.32 | 3.39 | 4.63 | 3.57 | 5.69 | 3.04 | 2.77 | 2.91 | 4.74 |
| — | +389.2% | +242.9% | +175.1% | +63.8% | +11.4% | +67.1% | +23.0% | +20.1% | -42.7% | -27.3% | -59.5% | -70.8% | |
| P/B Ratio | 0.70 | 1.08 | 1.36 | 2.15 | 2.00 | 2.14 | 3.42 | 2.92 | 4.77 | 2.80 | 3.16 | 3.46 | 4.69 |
| — | -49.6% | -60.2% | -26.4% | -58.0% | -23.5% | +8.1% | -15.6% | +1.7% | -50.8% | -29.2% | -57.5% | -71.5% | |
| P/FCF | — | — | — | — | — | — | — | 10.25 | 72.15 | 10.59 | 4.73 | 238.30 | 83.21 |
| — | — | — | — | — | — | — | -95.7% | -13.3% | +7.0% | -52.9% | +195.3% | -38.3% | |
| EV / EBITDA | 14.04 | — | — | — | 31.16 | 8.47 | 11.76 | 5.78 | 26.61 | 6.23 | 5.70 | 8.09 | 15.93 |
| — | — | — | — | +17.1% | +36.0% | +106.3% | -28.6% | +67.1% | -54.5% | -34.8% | -63.6% | -83.3% | |
| EV / EBIT | 14.43 | 5.94 | — | — | 32.03 | 6.92 | 57.35 | 5.28 | 26.86 | 5.76 | 5.82 | 8.25 | 16.49 |
| — | -14.2% | — | — | +19.2% | +20.2% | +885.4% | -36.0% | +62.9% | -58.1% | -35.4% | -64.3% | -84.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Semler Scientific, Inc.'s operating margin was -72.0% in Q3 2025, down 47.0 pp QoQ and down 109.4 pp YoY. The trailing four-quarter average of -105.1% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.5% | 91.5% | 91.0% | 89.4% | 91.1% | 91.4% | 91.3% | 92.2% | 77.5% | 93.2% | 93.4% | 93.0% | 91.4% |
| — | +0.1% | -0.3% | -3.0% | +17.5% | -1.9% | -2.3% | -0.9% | -15.2% | +1.4% | -0.1% | -0.1% | +12.5% | |
| Operating Margin | 37.2% | -72.0% | -25.0% | -352.0% | 28.5% | 37.5% | 37.0% | 43.9% | 16.8% | 38.6% | 38.6% | 34.4% | 26.2% |
| — | -292.0% | -167.6% | -902.5% | +70.3% | -2.9% | -4.2% | +27.7% | -36.1% | +21.4% | +10.5% | +22.2% | +77.0% | |
| Net Margin | 72.7% | 225.6% | 814.6% | -732.3% | 235.3% | 41.5% | 0.1% | 38.2% | 28.0% | 33.8% | 31.6% | 27.3% | 23.3% |
| — | +443.5% | +1071699.2% | -2017.7% | +739.2% | +22.8% | -99.8% | +39.9% | +20.3% | +29.2% | +15.0% | +13.9% | +78.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 27.0% | 4.0% | 24.6% | -33.0% | 18.5% | 6.9% | 0.0% | 8.1% | 5.9% | 8.1% | 9.3% | 8.5% | 6.0% |
| — | -41.5% | +174073.0% | -506.4% | +212.1% | -15.5% | -99.8% | -4.6% | -0.5% | +13.6% | +14.2% | +20.1% | +76.9% | |
| ROA | 25.7% | 3.0% | 16.4% | -24.3% | 17.6% | 6.3% | 0.0% | 7.5% | 5.4% | 7.1% | 8.1% | 7.5% | 5.2% |
| — | -52.4% | +126086.9% | -423.5% | +228.2% | -11.0% | -99.8% | +0.4% | +3.0% | +14.8% | +12.0% | +18.0% | +75.5% | |
| ROIC | 13.3% | -0.8% | -0.4% | -9.9% | 1.8% | 5.1% | 9.3% | 34.8% | 7.8% | 15.9% | 13.1% | 10.5% | 13.6% |
| — | -115.5% | -104.6% | -128.5% | -77.5% | -68.1% | -29.2% | +230.4% | -42.2% | -57.3% | -62.5% | -64.7% | -10.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 37.4% YoY to 1.97x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.25 | 0.25 | 0.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | +24750.0% | +16867.1% | +33476.1% | -86.4% | -60.1% | -52.4% | -51.6% | -49.3% | -49.7% | -44.7% | -40.7% | -38.3% | |
| Debt / EBITDA | 0.00 | — | — | — | 0.02 | 0.02 | 0.02 | 0.02 | 0.06 | 0.03 | 0.03 | 0.04 | 0.07 |
| — | — | — | — | -67.8% | -40.4% | -24.5% | -44.8% | -8.8% | -51.3% | -48.2% | -52.9% | -62.5% | |
| Current Ratio | 3.59 | 1.97 | 0.60 | 0.52 | 3.59 | 3.14 | 3.72 | 12.18 | 10.64 | 7.51 | 6.03 | 6.23 | 7.13 |
| — | -37.4% | -84.0% | -95.8% | -66.2% | -58.1% | -38.2% | +95.4% | +49.1% | +21.8% | -16.6% | -28.1% | -23.6% | |
| Quick Ratio | 3.54 | 1.95 | 0.58 | 0.51 | 3.54 | 3.09 | 3.66 | 12.11 | 10.56 | 7.45 | 5.98 | 6.18 | 7.06 |
| — | -36.9% | -84.2% | -95.8% | -66.5% | -58.6% | -38.7% | +96.1% | +49.5% | +22.2% | -16.4% | -27.9% | -23.4% | |
| Interest Coverage | — | -3.42 | -1.79 | -32.98 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SMLR stock.
Semler Scientific, Inc.'s current P/E is 4.0x. The average P/E over the last 3 quarters is 4.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Semler Scientific, Inc.'s current operating margin is 37.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Semler Scientific, Inc.'s business trajectory between earnings reports.